Hold Therapeutic Enoxaparin 24 Hours Before Stone Procedures
For patients on therapeutic-dose enoxaparin undergoing urological stone procedures (ureteroscopy, PCNL, or ESWL), hold the last dose 24 hours before the procedure. This timing balances bleeding risk with thromboembolic protection and is supported by established bridging protocols 1.
Pre-Procedure Management
Timing of Last Dose
- Stop therapeutic enoxaparin 24 hours before the procedure 2, 1
- For twice-daily dosing (1 mg/kg BID): give the last dose on the morning of the day before surgery (Day -1) at half the total daily dose 1
- For once-daily dosing (1.5 mg/kg daily): give the last full dose 24 hours pre-procedure
Special Consideration for Renal Impairment
- In patients with impaired renal function, hold enoxaparin for longer than 24 hours before surgery 2
- Enoxaparin accumulates in renal failure, requiring extended clearance time
- Consider checking anti-Xa levels if creatinine clearance <30 mL/min
Post-Procedure Resumption
Timing Based on Bleeding Risk
For most stone procedures (moderate bleeding risk):
- Resume therapeutic enoxaparin 24-48 hours post-procedure 1
- Ensure adequate hemostasis before restarting
For high-bleeding-risk procedures (PCNL):
- Consider low-dose prophylactic enoxaparin (40 mg daily) for the first 24-72 hours 1
- Resume full therapeutic dosing 48-72 hours post-procedure once bleeding has subsided 2, 1
Urological-Specific Evidence
The 2014 ICUD/AUA guideline specifically addresses stone procedures 2:
- Ureteroscopy with laser lithotripsy showed 23% required early postoperative transfusion when therapeutic anticoagulation was restarted early
- PCNL patients on anticoagulants had increased bleeding complications in the CROES database
- ESWL historically carried concerns about hemorrhage risk with anticoagulation
Clinical Algorithm
Pre-procedure (Day -1):
- Morning: Give half-dose therapeutic enoxaparin (if BID dosing)
- Confirm adequate renal function
Day of procedure (Day 0):
- No enoxaparin administered
- Proceed with stone procedure
Post-procedure:
- Day +1: Assess hemostasis; consider prophylactic-dose enoxaparin (40 mg) if high bleeding risk
- Day +2-3: Resume therapeutic dosing if hemostasis confirmed and no active bleeding
Important Caveats
High thromboembolic risk patients (mechanical heart valves, recent VTE within 3 months, atrial fibrillation with prior stroke) require careful risk-benefit assessment 2. The short-term VTE recurrence rate is low (5%) even with brief interruption 2.
Avoid the common pitfall of restarting therapeutic anticoagulation too early after PCNL—this procedure carries higher bleeding risk than ureteroscopy or ESWL. The urological literature specifically documents increased transfusion requirements when full anticoagulation resumes within 24 hours 2.
For patients bridging from warfarin: The same 24-hour pre-procedure hold applies, with warfarin stopped 5 days before surgery and bridging enoxaparin started 3 days pre-operatively 2, 1.